US government places $100 million order of Bavarian Nordic's Imvamune vaccine
Danish biotech firm Bavarian Nordic (OMX: BAVA) has announced a $100 million contract for its Imvamune smallpox vaccine with a division of the US Department of Health and Human Services.
The Biomedical Advanced Research and Development Authority (BARDA) division has followed up on its $133 million order for the vaccine in 2015 with a request for a smaller batch.
Under the new order, Bavarian Nordic will manufacture and store a bulk supply of Imvamune. This bulk material can be converted into freeze-dried Imvamune at a later date, once the freeze-drying manufacturing process has been transferred to a commercial line, and is approved by the US authorities.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze